Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response.
Adaptive Immunity
/ drug effects
Angiogenesis Inhibitors
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ therapeutic use
Bevacizumab
/ therapeutic use
Capillary Permeability
/ drug effects
Endothelial Cells
/ drug effects
Gene Expression Regulation, Neoplastic
Humans
Immunity, Innate
/ drug effects
Immunologic Factors
/ therapeutic use
Neoplasms
/ drug therapy
Neovascularization, Pathologic
/ genetics
Receptors, Vascular Endothelial Growth Factor
/ therapeutic use
Recombinant Fusion Proteins
/ therapeutic use
Signal Transduction
Sorafenib
/ therapeutic use
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-1
/ antagonists & inhibitors
Ramucirumab
angiogenesis
cancer
immune response
vascular endothelial growth factor
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 May 2021
04 May 2021
Historique:
received:
30
03
2021
revised:
27
04
2021
accepted:
02
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
16
6
2021
Statut:
epublish
Résumé
During tumor growth, angiogenesis is required to ensure oxygen and nutrient transport to the tumor. Vascular endothelial growth factor (VEGF) is the major inducer of angiogenesis and appears to be a key modulator of the anti-tumor immune response. Indeed, VEGF modulates innate and adaptive immune responses through direct interactions and indirectly by modulating protein expressions on endothelial cells or vascular permeability. The inhibition of the VEGF signaling pathway is clinically approved for the treatment of several cancers. Therapies targeting VEGF can modulate the tumor vasculature and the immune response. In this review, we discuss the roles of VEGF in the anti-tumor immune response. In addition, we summarize therapeutic strategies based on its inhibition, and their clinical approval.
Identifiants
pubmed: 34064508
pii: ijms22094871
doi: 10.3390/ijms22094871
pmc: PMC8124522
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
Recombinant Fusion Proteins
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
aflibercept
15C2VL427D
Bevacizumab
2S9ZZM9Q9V
Sorafenib
9ZOQ3TZI87
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Sci. 2019 Aug;110(8):2357-2367
pubmed: 31169331
Med Oncol. 2019 Nov 11;37(1):2
pubmed: 31713115
Front Immunol. 2019 May 09;10:1023
pubmed: 31156623
Biomed Res Int. 2015;2015:142359
pubmed: 26146612
J Immunol. 1998 Feb 1;160(3):1224-32
pubmed: 9570538
J Immunol. 2013 Apr 15;190(8):3939-48
pubmed: 23487420
Cancer Lett. 1997 Dec 9;120(2):203-11
pubmed: 9461038
Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
Int J Cancer. 1988 Jul 15;42(1):48-52
pubmed: 2455691
Nat Rev Drug Discov. 2006 Oct;5(10):835-44
pubmed: 17016424
Nature. 1993 Apr 29;362(6423):841-4
pubmed: 7683111
J Hematol Oncol. 2019 Mar 12;12(1):27
pubmed: 30866992
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81
pubmed: 27044098
Onco Targets Ther. 2018 Oct 17;11:6901-6909
pubmed: 30410348
J Clin Invest. 2017 Aug 1;127(8):3039-3051
pubmed: 28691930
Blood. 2015 Oct 22;126(17):2016-26
pubmed: 26286848
PLoS One. 2018 Jan 11;13(1):e0191040
pubmed: 29324807
Immunotherapy. 2017 Mar;9(3):289-302
pubmed: 28231720
J Clin Oncol. 2013 Apr 1;31(10):1341-7
pubmed: 23358972
JCI Insight. 2016 Jun 16;1(9):e85974
pubmed: 27699271
Nat Rev Drug Discov. 2011 Jun;10(6):417-27
pubmed: 21629292
Br J Cancer. 2009 Apr 7;100(7):1111-9
pubmed: 19277038
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
Angiogenesis. 2014 Jul;17(3):443-62
pubmed: 24146040
Cancer Lett. 2014 Nov 28;354(2):281-9
pubmed: 25157650
Nat Rev Clin Oncol. 2018 May;15(5):310-324
pubmed: 29434333
Front Immunol. 2020 Nov 05;11:598877
pubmed: 33250900
Biochim Biophys Acta Gen Subj. 2018 May;1862(5):1069-1078
pubmed: 29410184
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
Neoplasia. 2013 Feb;15(2):133-42
pubmed: 23441128
PLoS One. 2012;7(3):e33271
pubmed: 22413008
Nat Biotechnol. 2007 Aug;25(8):911-20
pubmed: 17664940
Endocr Relat Cancer. 2008 Dec;15(4):1069-74
pubmed: 18719091
Blood. 2003 Jun 15;101(12):4878-86
pubmed: 12586633
J Leukoc Biol. 2016 Nov;100(5):979-984
pubmed: 27406995
J Immunol. 2005 Jun 15;174(12):7665-75
pubmed: 15944267
Angiogenesis. 2020 May;23(2):231-247
pubmed: 31897911
Br J Cancer. 2012 Nov 20;107(11):1869-75
pubmed: 23169339
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Lett. 2018 Apr 1;418:176-184
pubmed: 29339213
Int J Mol Sci. 2019 Jan 27;20(3):
pubmed: 30691207
Nat Med. 2014 Jun;20(6):607-15
pubmed: 24793239
Nature. 1996 Apr 4;380(6573):439-42
pubmed: 8602242
Clin Cancer Res. 2017 Jan 15;23(2):587-599
pubmed: 27401249
Rom J Morphol Embryol. 2018;59(2):455-467
pubmed: 30173249
Cancer Immunol Immunother. 2014 Feb;63(2):81-99
pubmed: 24263240
Cancer Discov. 2016 Apr;6(4):414-29
pubmed: 26873347
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
Front Immunol. 2019 Jun 25;10:1445
pubmed: 31293594
Front Immunol. 2019 Apr 18;10:771
pubmed: 31057536
Curr Cancer Drug Targets. 2020;20(1):3-18
pubmed: 31729943
Future Oncol. 2017 Dec;13(28):2515-2535
pubmed: 28812378
Oncoimmunology. 2015 Jan 22;4(4):e998519
pubmed: 26137414
J Immunol. 2007 Feb 1;178(3):1505-11
pubmed: 17237399
Int J Mol Sci. 2020 Dec 03;21(23):
pubmed: 33287465
Clin Exp Immunol. 2013 Jun;172(3):500-6
pubmed: 23600839
Cancer Discov. 2016 Aug;6(8):827-37
pubmed: 27301722
Nat Med. 2003 May;9(5):562-7
pubmed: 12704383
Cancer Cell. 2009 Mar 3;15(3):220-31
pubmed: 19249680
J Immunol. 2005 Jan 1;174(1):215-22
pubmed: 15611243
J Mol Med (Berl). 2013 Oct;91(10):1199-205
pubmed: 23686259
Exp Cell Res. 2017 Oct 1;359(1):179-184
pubmed: 28756894
FASEB J. 2015 Jan;29(1):227-38
pubmed: 25361735
Pharmacol Ther. 2017 Nov;179:171-187
pubmed: 28564583
J Immunother. 2010 Nov-Dec;33(9):991-8
pubmed: 20948437
Trends Biochem Sci. 2003 Sep;28(9):488-94
pubmed: 13678960
Circ Res. 2003 Mar 21;92(5):485-92
pubmed: 12600879
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Angiogenesis. 2019 Feb;22(1):167-183
pubmed: 30238211
Nat Rev Drug Discov. 2017 Sep;16(9):635-661
pubmed: 28529319
Clin Cancer Res. 2003 Sep 15;9(11):4221-6
pubmed: 14519649
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Front Oncol. 2014 Apr 02;4:70
pubmed: 24765614
Nat Commun. 2017 Nov 17;8(1):1597
pubmed: 29150606
Cancer Res. 2003 May 1;63(9):2322-9
pubmed: 12727857
Nature. 1996 Apr 4;380(6573):435-9
pubmed: 8602241
Cancer Cell. 2004 Oct;6(4):409-21
pubmed: 15488763
Front Immunol. 2017 Apr 12;8:424
pubmed: 28446910
Cell Metab. 2018 Feb 6;27(2):281-298
pubmed: 29129785
Crit Rev Oncol Hematol. 2015 Dec;96(3):569-76
pubmed: 26224565
Oncotarget. 2012 Sep;3(9):921-39
pubmed: 22948112
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8
pubmed: 16891410
Curr Opin Genet Dev. 2005 Feb;15(1):102-11
pubmed: 15661540
Nature. 1995 Jul 6;376(6535):62-6
pubmed: 7596435
Cancer Res. 2009 Mar 15;69(6):2514-22
pubmed: 19276342
Front Oncol. 2020 Feb 27;10:221
pubmed: 32175278
Ann Endocrinol (Paris). 2007 Dec;68(6):438-48
pubmed: 17991452
Nature. 1992 Oct 29;359(6398):845-8
pubmed: 1279432
Int J Cancer. 2014 Jan 15;134(2):319-31
pubmed: 23818246
J Allergy Clin Immunol. 2009 May;123(5):1142-9, 1149.e1-5
pubmed: 19275959
Biomed Res Int. 2015;2015:549412
pubmed: 26146622
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4470-5
pubmed: 27044097
Nat Rev Cancer. 2003 Jun;3(6):401-10
pubmed: 12778130
PLoS One. 2020 Dec 31;15(12):e0244366
pubmed: 33382742
J Immunother Cancer. 2018 Oct 11;6(1):106
pubmed: 30314524
J Exp Med. 2012 Oct 22;209(11):2001-16
pubmed: 23045606
J Immunol. 2004 Jan 15;172(2):1227-36
pubmed: 14707101
J Exp Med. 2015 Feb 9;212(2):139-48
pubmed: 25601652
Oncotarget. 2017 Feb 28;8(9):16052-16074
pubmed: 28030802
N Engl J Med. 2010 Mar 11;362(10):875-85
pubmed: 20220182
Front Oncol. 2015 Sep 22;5:202
pubmed: 26442214
PLoS One. 2018 Mar 22;13(3):e0194679
pubmed: 29566045
Cancer Res. 2018 Aug 1;78(15):4270-4281
pubmed: 29776963
Clin Cancer Res. 2000 May;6(5):1755-66
pubmed: 10815894